Instructions for Miramistin vaginal suppositories 15 mg
ATC codes Miramistin
D08AJ Quaternary Ammonium Compounds
Clinical-pharmacological groups / Group affiliation
Antiseptic for local use
Active substance Miramistin
benzyl-dimethyl-myristoylamino-propylammonium chloride monohydrate
Pharmaco-therapeutic group Miramistin
Antiseptic agent
Storage Conditions Miramistin
The drug should be stored in a place inaccessible to children at a temperature not higher than 25 ° C.
Best before date
The shelf life is three years. Do not use the drug after the expiry date
Brief Description Miramistin
Clinical-pharmacological group: Antiseptic for local use in gynecology.
Rectal suppositories are intended for treatment and prevention of respiratory system disorders and may be used as a photoactive agent in scope of treatment and prevention of neurological conditions.
Testimony Miramistin
- Prevention and treatment of inflammatory diseases in gynecology (vulvovaginite, bacterial vaginosis);
- prevention and treatment of festering postnatal injuries, vaginal wounds, and postnatal infections.
Method of use and dosage Miramistin
Intravaginally.
The suppositories are released from the contour packing prior to use.
One suppository ten mg twice a day (12 h intervals) or one suppository five mg once a day (24 h intervals) for seven days.
Apply the suppository as deeply as possible into the vagina; do not use soap or soap-based soap for genital toilet for two hours before and 2 hours after intravaginal administration of Miramistin (only clean water should be used).
Pharmacological effect Miramistin
Miramistin has a broad spectrum of antimicrobial activity, including hospital strains that are resistant to antibiotics.
The preparation has a pronounced bactericidal effect in relation to gram-positive (Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae) and gram-negative (Pseudomonas aeruginosa, Escherichia coli, Klebsiella spp.), aerobic and anaerobic bacteria, which are determined in the form of monocultures and microbial associations, including hospital strains with antibiotic polyresistance.
- Miramistin Nosology (ICD codes)
- A51
- Early syphilis
- A52
- Late syphilis
- A54
- Gonococcal infection
- A56.0
- Chlamydia infections of the lower urinary tract
- A56.1
- Chlamydia infections of pelvic organs and other urinary organs
- A59
- Trichomoniasis
- A60
- Anogenital herpetic virus infection [herpes simplex]
- Candidiasis stomatitis
- B37.2
- Candidiasis of the vulva and vagina
- B37.4
- Candidiasis of other urogenital localizations
- N37.0
- Urethritis in diseases classified in other headings
- N41
- Inflammatory disease of the uterus, except the cervix (including endometritis, myometritis, metritol, pyometra, abscess of the uterus)
- N72
- Inflammatory disease of the cervix (incl. cervicite, endocervicite, exocervicite)
- N76
- Other inflammatory diseases of the vagina and vulva
- N77.1
- Vaginitis, vulvite and vulvovaginitis for infectious and parasitic diseases classified in other headings
- O08.0
- Genital and pelvic tract infection caused by abortion, ectopic and molar pregnancy
- O70
- Laceration ruptures in childbirth
- O71
- Other obstetric injuries
